175 related articles for article (PubMed ID: 23800161)
1. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; Mulder PG; VAN Schaik RH; Kuipers EJ; Kooiman JC; Geus WP
Aliment Pharmacol Ther; 2010 Jan; 31(1):150-9. PubMed ID: 19785625
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
Hartmann D; Eickhoff A; Damian U; Riemann JF; Schilling D
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):133-7. PubMed ID: 17272998
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers.
Liu D; Yang H; Jiang J; Nagy P; Shen K; Qian J; Hu P
J Clin Pharmacol; 2016 Jul; 56(7):816-26. PubMed ID: 26970404
[TBL] [Abstract][Full Text] [Related]
6. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
7. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
[TBL] [Abstract][Full Text] [Related]
8. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
10. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
11. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
[TBL] [Abstract][Full Text] [Related]
12. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs.
Seo DH; Lee JB; Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2019 Mar; 33(2):531-535. PubMed ID: 30548689
[TBL] [Abstract][Full Text] [Related]
15. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
16. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.
Wang Y; Yuan Y; Meng L; Fan H; Xu J; Zhang H; Wang M; Yuan H; Ou N; Zhang H; Chao Y; Shi R
Eur J Clin Pharmacol; 2011 Jan; 67(1):25-31. PubMed ID: 21110014
[TBL] [Abstract][Full Text] [Related]
17. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
18. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
19. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Kagami T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Digestion; 2015; 91(4):277-85. PubMed ID: 25924819
[TBL] [Abstract][Full Text] [Related]
20. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
